- Home
- OM vs ACET Comparison
OM vs ACET Comparison
Compare OM & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- ACET
- Stock Information
- Founded
- OM 2003
- ACET 1947
- Country
- OM United States
- ACET United States
- Employees
- OM N/A
- ACET N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- OM Health Care
- ACET Health Care
- Exchange
- OM Nasdaq
- ACET Nasdaq
- Market Cap
- OM 50.5M
- ACET 44.4M
- IPO Year
- OM 2020
- ACET N/A
- Fundamental
- Price
- OM $11.01
- ACET $0.53
- Analyst Decision
- OM Buy
- ACET Buy
- Analyst Count
- OM 2
- ACET 6
- Target Price
- OM $45.00
- ACET $6.00
- AVG Volume (30 Days)
- OM 141.8K
- ACET 597.2K
- Earning Date
- OM 05-07-2025
- ACET 05-13-2025
- Dividend Yield
- OM N/A
- ACET N/A
- EPS Growth
- OM N/A
- ACET N/A
- EPS
- OM N/A
- ACET N/A
- Revenue
- OM $113,689,000.00
- ACET N/A
- Revenue This Year
- OM $8.98
- ACET N/A
- Revenue Next Year
- OM $12.74
- ACET N/A
- P/E Ratio
- OM N/A
- ACET N/A
- Revenue Growth
- OM N/A
- ACET N/A
- 52 Week Low
- OM $5.85
- ACET $0.45
- 52 Week High
- OM $78.30
- ACET $2.29
- Technical
- Relative Strength Index (RSI)
- OM 52.11
- ACET 34.42
- Support Level
- OM $10.30
- ACET $0.45
- Resistance Level
- OM $11.65
- ACET $0.61
- Average True Range (ATR)
- OM 1.20
- ACET 0.07
- MACD
- OM 0.08
- ACET -0.01
- Stochastic Oscillator
- OM 65.42
- ACET 21.18
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.